A Cohort Study on Influenza Vaccine and All-Cause Mortality in Older Adults: Methodological Concerns and Public Health Implications.


Journal

Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074

Informations de publication

Date de publication:
08 2022
Historique:
accepted: 01 06 2022
pubmed: 23 7 2022
medline: 10 8 2022
entrez: 22 7 2022
Statut: ppublish

Résumé

In 2020, the restrictions adopted to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic led to an unprecedented reduction in influenza-related burden. As such, the reduced chance to characterize the circulating virus strains might have increased the risk of vaccine mismatch for the forthcoming winter seasons. The role of an effective influenza vaccination campaign might therefore assume even more value, especially for frail and multimorbid older individuals. Methodological concerns on confounding by indication are always debated in vaccine effectiveness studies and it might be instrumental to give a pragmatic message on an individual's responsibility to receive the influenza vaccine. We therefore investigated the role of specific confounders to explain the association between influenza vaccine and mortality among older adults. Using a primary care database, we formed a cohort of patients aged 65 years or older who were actively registered with their general practitioner (GP) at the beginning of each of nine influenza seasons through to the 2018/2019 season. The study index date was the related seasons' starting date. Exposure to the influenza vaccine was operationally defined in the 2 months preceding the index date up to 2 weeks before the exit date. Cox regression models were estimated to calculate hazard ratios (HRs) and their 95% confidence intervals (CI) of death between vaccinated and unvaccinated patients in a time-dependent fashion. The potential confounders sequentially entered the model based on their increasing effect size observed in univariate analyses. Over the 10 years under study, the influenza vaccine showed a significant protective effect in terms of mortality, reaching 13% reduction (HR 0.87, 95% CI 0.80-0.95) in the 2018/2019 influenza season. When we estimated the multivariate model by sequentially adding the potential confounders, there was an inversion of HR (below the unit) that was significantly explained by the covariates coding for a prior history of lower respiratory tract infections and the presence of the pneumococcal vaccine. In the current pandemic scenario, we cannot divert attention to proper use of face masks, social distancing, and hand hygiene, which are important measures to prevent influenza and other respiratory viral infections. Nonetheless, their effectiveness might be negligible without acceptable coverage for influenza vaccine, especially in older patients with a history of lower respiratory tract infections, which appears to be the main source of confounding by indication.

Identifiants

pubmed: 35867212
doi: 10.1007/s40266-022-00958-7
pii: 10.1007/s40266-022-00958-7
pmc: PMC9305032
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

645-656

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Nielsen J, Krause TG, Mølbak K. Influenza-associated mortality determined from all-cause mortality, Denmark 2010/11-2016/17: The FluMOMO model. Influenza Other Respir Viruses. 2018;12(5):591–604.
doi: 10.1111/irv.12564
Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: A systematic review and meta-analysis. J Am Heart Assoc. 2021;10(6): e019636.
doi: 10.1161/JAHA.120.019636
Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine. 2017;35:513–20.
doi: 10.1016/j.vaccine.2016.12.011
DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. N Engl J Med. 2014;371:635–45.
Chung H, Buchan SA, Campigotto A, Campitelli MA, Crowcroft NS, Dubey V, et al. Influenza Vaccine Effectiveness against All-Cause Mortality following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario. Canada Clin Infect Dis. 2021;73:E1191–9.
doi: 10.1093/cid/ciaa1862
Walzer P, Estève C, Barben J, Menu D, Cuenot C, Manckoundia P, et al. Impact of Influenza Vaccination on Mortality in the Oldest Old: A Propensity Score-Matched Cohort Study. Vaccines. Vaccines (Basel); 2020;8:356.
Marill MC. After flu vaccine mismatch, calls for delayed selection intensify. Nat Med. 2015;21:297–8.
doi: 10.1038/nm0415-297
Ministry of Health. Influenza. Available at: https://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto
Andrew MK, Bowles SK, Pawelec G, Haynes L, Kuchel GA, McNeil SA, et al. Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. Drugs Aging. 2019;36(1):29–37.
doi: 10.1007/s40266-018-0597-4
Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47:749–54.
doi: 10.1111/j.1532-5415.1999.tb01603.x
Pawelec G, Bronikowski A, Cunnane SC, Ferrucci L, Franceschi C, Fülöp T, et al. The conundrum of human immune system “senescence.” Mech Ageing Dev. 2020;192: 111357.
doi: 10.1016/j.mad.2020.111357
McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G. The immune response to influenza in older humans: Beyond immune senescence. Immun Ageing. 2020;17:1–10.
doi: 10.1186/s12979-020-00181-1
Andrew MK, Shinde V, Ye L, Hatchette T, Haguinet F, Dos SG, et al. The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. J Infect Dis J Infect Dis. 2017;216:405–14.
doi: 10.1093/infdis/jix282
Vetrano DL, Triolo F, Maggi S, Malley R, Jackson TA, Poscia A, et al. Fostering healthy aging: The interdependency of infections, immunity and frailty. Ageing Res Rev. 2021;69: 101351.
doi: 10.1016/j.arr.2021.101351
Filippi A, Vanuzzo D, Bignamini AA, Mazzaglia G, Cricelli C, Catapano AL. The database of Italian general practitioners allows a reliable determination of the prevalence of myocardial infarction. Ital Heart J. 2005;6:311–4.
pubmed: 15902929
Dentali F, Fontanella A, Cohen AT, Simonetti M, Parretti L, Marconi E, et al. Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. Thromb Haemost. 2020;120:692–701.
doi: 10.1055/s-0040-1701483
Lapi F, Marconi E, Simonetti M, Baldo V, Rossi A, Sessa A, et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines. 2019;18(6):663–70.
doi: 10.1080/14760584.2019.1622418
Rastogi S, Gross PA, Bonelli J, Dran S, Levandowski RA, Russo C, et al. Time to peak serum antibody response to influenza vaccine. Clin Diagn Lab Immunol. 1995;2(1):120–1.
doi: 10.1128/cdli.2.1.120-121.1995
Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168:329–35.
doi: 10.1093/aje/kwn135
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81.
doi: 10.1093/eurheartj/ehw106
Wang Q, Koval JJ, Mills CA, Lee KID. Determination of the Selection Statistics and Best Significance Level in Backward Stepwise Logistic Regression. Taylor & Francis Group. 2008;37:62–72. https://doi.org/10.1080/03610910701723625 .
doi: 10.1080/03610910701723625
Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines [cited 2022 Apr 27]. Available at: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-systematic-review-efficacy-vaccines
Delaney JA, Daskalopoulou SS, Brophy JM, Steele RJ, Opatrny L, Suissa S. Lifestyle variables and the risk of myocardial infarction in the general practice research database. BMC Cardiovasc Disord. 2007;7:38.
doi: 10.1186/1471-2261-7-38
Delaney JAC, Moodie EEM, Suissa S. Validating the effects of drug treatment on blood pressure in the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2008;17:535–45.
doi: 10.1002/pds.1553

Auteurs

Francesco Lapi (F)

Health Search, Italian College of General Practitioners and Primary Care, Via del Sansovino 179, 50141, Florence, Italy. lapi.francesco@simg.it.

Ettore Marconi (E)

Health Search, Italian College of General Practitioners and Primary Care, Via del Sansovino 179, 50141, Florence, Italy.

Maria Rosaria Gualano (MR)

Department of Public Health Sciences, University of Tourin, Turin, Italy.

Davide Liborio Vetrano (DL)

Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
Stockholm Gerontology Research Center, Stockholm, Sweden.

Ignazio Grattagliano (I)

Italian College of General Practitioners and Primary Care, Florence, Italy.

Alessandro Rossi (A)

Italian College of General Practitioners and Primary Care, Florence, Italy.

Claudio Cricelli (C)

Italian College of General Practitioners and Primary Care, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH